Gastrointestinal Cancer News

In an opinion essay published in Annals of Internal Medicine, several European clinicians argue that the current colorectal cancer screening recommendations by the U.S. Preventive Services Task Force lack strength and quality of evidence. “We are surprised by the latest update of the recommendations for colorectal cancer screening from the U.S. Preventive Services Task Force (USPSTF),” Michael Bretthauer, MD, PhD, from the KG Jebsen Center for Colorectal Cancer at the University of Oslo in Norway, and colleagues wrote. “Contrary to the principles of evidence-based medicine, the guidelines provided equally strong recommendations for tests with very different quality of evidence for benefits and harms.”

Bayer announced it has submitted a supplemental New Drug Application to the FDA for Stivarga as a second-line systemic treatment for patients with unresectable hepatocellular carcinoma.

The use of transarterial chemoembolization with radiotherapy led to improved survival outcomes for patients with unresectable hepatocellular carcinoma and portal vein tumor thrombus, compared with patients who underwent transarterial chemoembolization alone, per published findings in Hepatology Research.

Patients with cancer may have an increased risk for treatment-related and -unrelated injuries in the periods preceding and following their cancer diagnosis, according to the results of a registry study conducted in Sweden.

Prediagnosis obesity may be a risk factor for overall and individual secondary primary cancers in male cancer survivors, according to a large cohort study.

High BMI, greater waist circumference and type 2 diabetes appeared to increase risk for liver cancer, according to an analysis of data from the Liver Cancer Pooling Project published in Cancer Research.

Researchers developed an effective risk model for measuring long-term outcomes of nodules with undetermined malignant potential and hepatocellular carcinoma progression in patients with hepatitis B virus-related cirrhosis, per published findings in the American Journal of Gastroenterology.

Use of proton pump inhibitors reduced the efficacy of capecitabine in patients with advanced gastroesophageal cancer, according to an analysis of results from a randomized clinical trial.

The FDA has announced several decisions related to hematology and oncology treatments in the past 2 weeks.

Patients diagnosed with left-sided colon cancer appeared to have nearly a 20% reduced risk for death compared with those with right-sided tumors, according to results of a systematic review and meta-analysis published in JAMA Oncology.